跳至主要内容
临床试验/KCT0003235
KCT0003235已完成未知

Electro-acupuncture for treating the treatment-resistant insomnia : randomized controlled, assessor-blinded, pilot clinical trial

Pusan National University Korean Medicine Hospital0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19?(Year) 至 80?(Year)(—)
性别
All

入选标准

  • 1. Patients aged 19 years - 80 years
  • 2. Patinets who continous taking medication for improving insomnia symptoms over the last 3 months, and not changed their regular medication type or doseage to improve insomnia within the last 2 weeks
  • 3. Total score in the Insomnia Severity Index (ISI)=15 points
  • 4. fulfilment of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM-5) diagnostic criteria for insomnia disorder
  • 5. Willingness to participate in the trial and having provided written consent

排除标准

  • 1. Having undergone Korean medical treatment (eg, acupuncture, moxibustion, cupping, herbal medicine) within last 2 weeks for improving insomnia
  • 2. Initiation the dietary supplement regimen or non-pharmacological therapies (eg, cognitive behavioural therapy, meditation, etc) to alleviate insomnia within the last 2 weeks or plans for initiation during the trial.
  • 3. The patients with unstable(not controlled) schizophrenia, mania, bipolar disorder within last 6 months, or a subscale of either anxiety or depression in Hamilton Anxiety and Depression Scale score =11 points
  • 4. The patients with substance abuse/dependence within last 6 months
  • 5. Having experienced suicide/murder/self-injury attempt
  • 6. Working shifts or changes in day/night work schedule that could impact circadian rhythm
  • 7. Suffering from pain severe enough to cause sleep disturbance or presence of any disease that could cause insomnia
  • 8. Taking haemostatic agents (eg, Greenmono, Advate, Monoclate-P, Facnyne, BeneFix) because of cardiovascular or haemostatic disorders
  • 9. Abnormal findings in thyroid function test (abnormal level of free thyroxine (free T4) and thyroid-stimulating hormone (TSH) <0.1 µIU/mL or TSH >5.1 µIU/mL)
  • 10. Inadequate findings in laboratory test(total bilirubin> 2 times compared to the normal upper limit in research institute, ALT(Alanine transaminase) or AST(Aspartate transaminase) > 2.5 times compared to the normal upper limit in research institute, Creatinine > 2.5 times compared to the normal upper limit in research institute, WBC count < 1,500 ? or =10,000 ?, Absolute Neutrophil Count(ANC)< 1,000, platelets count < 75,000/µL, positive in urine HCG, or other abnormal findings that could impact the trial by investigator’s decision)
  • 11. Diagnosed serious chronic disease (e.g. malignant tumor, active pulmonary tuberculosis, chronic liver disease or chronic kidney disease ect.)
  • 12. History of hypersensitivity reactions to acupuncture or inability to cooperate with acupuncture therapy
  • 13. The presence of implants that could interfere with EA or a history of hypersensitivity reactions to electrostimulation
  • 14. Pregnancy, lactation or planning to become pregnant
  • 15. Having participated in other clinical trials within 4 weeks of the beginning of the trial
  • 16. Difficulty complying with the study protocol(treatment, visiting, filling in questionnaries)
  • 17. Subjects who are not appropriate by investigator’s decision

研究者

发起方
Pusan National University Korean Medicine Hospital

相似试验